Wolfgang Miesbach Discusses AAV Gene Therapy Safety in Hemophilia B: NEJM Correspondence Highlights Cancer Monitoring
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on Linkedin:
“Happy to Share: Our NEJM Correspondence on AAV Gene Therapy in Severe Hemophilia B is Published Today! I am delighted that our letter to the editor on gene therapy and cancer surveillance—written together Flora Peyvandi and Glenn Pierce —is now published in the New England Journal of Medicine (NEJM)!
This correspondence addresses the recent 13-year follow-up paper by Ulrike Reiss et al., reporting two cancer cases after AAV gene therapy. Importantly, out of the total number of malignancies reported so far in hemophilia gene therapy trials, a relation to gene therapy has always been excluded.
AAV gene therapy offers transformative clinical benefits, but even rare theoretical risks (such as vector integration) require our field to be proactive, and vigilant.
Our comment emphasizes why molecular safety monitoring should go far beyond basic PCR, advocating for robust standards like vector integration mapping and whole-genome sequencing and standardisation of methods is needed.
We also call for harmonized international frameworks (e.g., the WFH-GTR registry) and industry-supported, accessible postmarketing monitoring—ensuring safety without burdening patients.”
Find more information here.
Stay in tune with Hemostasis Today.
-
Feb 26, 2026, 15:24Nancy Shapiro: Excited to See This Publication on Current Landscape of Anticoagulation Stewardship Released
-
Feb 26, 2026, 15:15Ahmed Nasreldein: Stay Current on Key Updates in Ischemic and Hemorrhagic Stroke
-
Feb 26, 2026, 15:15Shannon Farmer: What Happens to Vital Signs Pre and Post 1-Unit and 2-Unit RBC Transfusion?
-
Feb 26, 2026, 15:08Emmanuel J Favaloro: When Is A ‘Subtype’ of VWD Not Really VWD?
-
Feb 26, 2026, 15:03Gregory Piazza: Importance of Recognizing PE As A Wide Spectrum of Presentations and Greater Range of Adverse Outcomes
-
Feb 26, 2026, 14:57Abdulla A. Damluji: Sex As An Effect Measure Modifier Between Frailty and Outcomes in AMI Patients
-
Feb 26, 2026, 14:48Ney Carter Borges: The APERITIF Trial Clarifies Rivaroxaban’s Role in LVT
-
Feb 26, 2026, 14:44Wolfgang Miesbach: Synovitis and Haemophilia in Focus at GTH2026
-
Feb 26, 2026, 14:40Al-Ola Abdallah: How Much Does It Cost to Publish in Hematology and Oncology Journals